B. Braun Medical believes that demand is likely to increase for its Metha Total Hip Replacement (THR) prosthesis.
The prosthesis offers long-term benefits over traditional metal-on-metal resurfacing procedures as its ceramic contact surfaces prevent the possibility of harmful metal ions entering the bloodstream.
It is therefore ideal for many of the younger patients who need hip replacement surgery and the company is expecting a 50 per cent increase in UK sales for 2008.
Phil Housden, orthopaedic consultant at Kent and Canterbury Hospital, commented: "With increasingly active lifestyles, there is an equally increasing demand for hip replacements which offer younger patients the minimal amount of surgery, offering a long-term solution and providing the maximum amount of mobility."
Mr Housden claimed that the company's hip prosthesis allows the surgeon to fine-tune the implant to achieve the "best possible result".
The implant also benefits from its small size, which means that surgeons can perform minimally invasive surgery and remove a nominal amount of bone and tissue.
What's better? Private or NHS healthcare?